ES2554531T3 - Procedimientos basados en los microARN para el diagnóstico, pronóstico y tratamiento del cáncer de pulmón - Google Patents

Procedimientos basados en los microARN para el diagnóstico, pronóstico y tratamiento del cáncer de pulmón Download PDF

Info

Publication number
ES2554531T3
ES2554531T3 ES12165734.0T ES12165734T ES2554531T3 ES 2554531 T3 ES2554531 T3 ES 2554531T3 ES 12165734 T ES12165734 T ES 12165734T ES 2554531 T3 ES2554531 T3 ES 2554531T3
Authority
ES
Spain
Prior art keywords
mir
seq
forerunner
level
name sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12165734.0T
Other languages
English (en)
Inventor
Carlo Croce
Nozomu Yanaihara
Curtis Harris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State University Research Foundation
Original Assignee
Ohio State University Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State University Research Foundation filed Critical Ohio State University Research Foundation
Application granted granted Critical
Publication of ES2554531T3 publication Critical patent/ES2554531T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un procedimiento para diagnosticar si un sujeto tiene cáncer de pulmón, que comprende la medición del nivel de productos génicos de miR en una muestra de tejido pulmonar de ensayo de dicho sujeto, en el que una alteración en el nivel de los productos génicos de miR en la muestra de ensayo, con respecto al nivel de los correspondientes productos génicos de miR en una muestra de control, es indicativa de que el sujeto tiene cáncer de pulmón, donde los productos génicos de miR comprenden un grupo de productos génicos de miR, consistiendo dicho grupo en miR-21, miR-205 y miR-126*; y donde el nivel de los productos génicos del miR-21 y del miR-205 en la muestra de ensayo son mayores que el nivel del correspondiente producto génico de miR en la muestra de control y donde el nivel del producto génico del miR- 126* en la muestra de ensayo es menor que el nivel del correspondiente producto génico del miR en la muestra de control.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
Las Tablas 1a y 1b describen las secuencias de nucleótidos de microARN humanos precursores y maduros. Tabla 1a-Secuencias de precursores de microARN humano
Nombre del Precursor
Secuencia (de 5’ a 3’)* SEC ID Nº
let-7a-1
1
let-7a-2
2
let-7a-3
3
let-7a-4
imagen6 4
let-7b
imagen7 5
let-7c
6
let-7d
7
let-7d-bl
8
let-7d-v2
9
let-7e
10
let-7f-1
11
let-7f-2-1
12
let-7f-2-2
13
let-7g
14
Nombre del Precursor
Secuencia (de 5’ a 3’)* SEC ID Nº
let-7i
15
miR-1b-1-1
imagen8 16
miR-1b-1-2
17
miR-1b-2
18
miR-1b
imagen9 19
miR-1d
imagen10 20
miR-7-1a
21
miR-7-1b
22
miR-7-2
23
miR-7-3
24
miR-9-1
25
miR-9-2
26
miR-9-3
imagen11 27
miR-10a
28
Nombre del Precursor
Secuencia (de 5’ a 3’)* SEC ID Nº
miR-10b
29
miR-15a-2
30
miR-15a
31
miR-15b-1
32
miR-15b-2
33
miR-16-1
imagen12 34
miR-16-2
35
miR-16-13
36
miR-17
37
miR-18
38
miR-18-13
imagen13 39
miR-19a
40
miR-19a-13
41
miR-19b-1
42
miR-19b-2
43
miR-19b-13
imagen14 44
Nombre del Precursor
Secuencia (de 5’ a 3’)* SEC ID Nº
miR-19b-X
45
miR-20 (miR-20a)
46
miR-21
47
miR-21-17
imagen15 48
miR-22
49
miR-23a
50
miR-23b
51
miR-23-19
52
miR-24-1
53
miR-24-2
54
miR-24-19
55
miR-24-9
56
miR-25
57
miR-26a
58
miR-26a-1
59
miR-26a-2
60
miR-26b
61
miR-27a
62
Nombre del Precursor
Secuencia (de 5’ a 3’)* SEC ID Nº
miR-27b-1
63
miR-27b-2
64
miR-27-19
65
miR-28
66
miR-29a-2
imagen16 67
miR-29a
68
miR-29b-1
69
miR-29b-2
70
miR-29c
71
miR-30a
72
miR-30b-1
73
miR-30b-2
imagen17 74
miR-30c
75
miR-30d
76
miR-30e
77
miR-31
78
miR-32
79
Nombre del Precursor
Secuencia (de 5’ a 3’)* SEC ID Nº
miR-33b
80
miR-33b-2
imagen18 81
miR-33
82
miR-34-a
imagen19 83
miR-34-b
84
miR-34-c
85
miR-91-13
86
miR-92-1
87
miR-92 -2
88
miR-93-1 (miR93-2)
89
miR-95-4
90
miR-96-7
91
miR-97-6 (miR30*)
92
miR-98
93
miR-99b
94
Nombre del Precursor
Secuencia (de 5’ a 3’)* SEC ID Nº
miR-99a
95
miR-100-1/2
96
miR-100-11
97
miR-101-1/2
98
miR-101
99
miR-101-1
100
miR-101-2
101
miR-101-9
102
miR-102-1
103
miR-102-7.1 (miR-102-7.2)
104
miR-103-2
105
miR-103-1
106
miR-104-17
107
miR-105-1
108
miR-105-2
imagen20 109
Nombre del Precursor
Secuencia (de 5’ a 3’)* SEC ID Nº
miR-106-a
110
miR-106-b
imagen21 111
miR-107
imagen22 112
miR-108-1pequeño
113
miR-108-2pequeño
imagen23 114
miR-122a-1
115
miR-122a-2
116
miR-123
imagen24 117
miR-124a-1
118
miR-124a-2
imagen25 119
miR-124a-3
120
miR-124a
121
miR-124b
imagen26 122
miR-125a-1
123
miR-125a-2
124
miR-125b-1
125
miR-125b-2
126
Nombre del Precursor
Secuencia (de 5’ a 3’)* SEC ID Nº
miR-126-1
127
miR-126-2
128
miR-127-1
129
miR-127-2
130
miR-128a
131
miR-128b
132
miR-128
133
miR-129-1
134
miR-129-2
135
miR-130a
imagen27 136
miR-131-1
imagen28 137
miR-131-3
138
miR-131
139
miR-132-1
140
miR-132-2
141
miR-133a-1
142
miR-133a-2
143
miR-133
imagen29 144
miR-133b
145
Nombre del Precursor
Secuencia (de 5’ a 3’)* SEC ID Nº
miR-133bpequeño
146
miR-134-1
imagen30 147
miR-134-2
imagen31 148
miR-135a-1
149
miR-135a-2 (miR135-2)
150
miR-135
151
miR-135b
152
miR-136-1
153
miR-136-2
154
miR-137
155
miR-138-1
156
miR-138-2
157
miR-138
158
miR-139
159
miR-140
160
miR-140as
161
miR-140s
162
miR-141-1
163
Nombre del Precursor
Secuencia (de 5’ a 3’)* SEC ID Nº
miR-141-2
164
miR-142
165
miR-143-1
166
miR-143-2
167
miR-144-1
168
miR-144-2
169
miR-145-1
170
miR-1 45-2
171
miR-146-1
172
miR-146-2
173
miR-147
174
miR-148a (miR148)
175
miR-148b
imagen32 176
miR-148bpequeño
177
miR-149-1
178
miR-149-2
179
miR-150-1
180
miR-150-2
181
miR-151
imagen33 182
Nombre del Precursor
Secuencia (de 5’ a 3’)* SEC ID Nº
miR-151-2
183
miR-152-1
imagen34 184
miR-152-2
185
miR-153-1-1
186
miR-153-1-2
187
miR-153-2-1
imagen35 188
miR-153-2-2
189
miR-154-1
190
miR-154-2
191
miR-155
192
miR-156 = miR157=solapamiento miR-141
imagen36 193
miR-158pequeño = miR192
194
miR-159-1pequeño
195
miR-161pequeño
imagen37 196
miR-163-1bpequeño
197
miR-163-3pequeño
imagen38 198
miR-162
199
Nombre del Precursor
Secuencia (de 5’ a 3’)* SEC ID Nº
miR-175pequeño =miR224
200
miR-177pequeño
201
miR-180pequeño
imagen39 202
miR-181a
203
miR-181b-1
204
miR-181b-2
205
miR-181c
206
miR-182-as
207
miR-182
208
miR-183
209
miR-184-1
210
miR-184-2
211
miR-185-1
212
miR-185-2
213
miR-186-1
214
Nombre del Precursor
Secuencia (de 5’ a 3’)* SEC ID Nº
miR-186-2
215
miR-187
216
miR-188-1
217
miR-188-2
218
miR-189-1
219
miR-189-2
220
miR-190-1
221
miR-190-2
222
miR-191-1
223
miR-191-2
224
miR-192-2/3
225
miR-192
226
miR-193-1
227
miR-193-2
228
miR-194-1
229
miR-194-2
230
Nombre del Precursor
Secuencia (de 5’ a 3’)* SEC ID Nº
miR-195-1
231
miR-195-2
232
miR-196-1
233
miR-196a-1
imagen40 234
miR-196a-2 (miR196-2)
235
miR-196
236
miR-196b
237
miR-197
238
miR-197-2
239
miR-198
imagen41 240
miR-199a-1
241
miR-199a-2
242
miR-199b
243
miR-199s
244
miR-200a
245
miR-200b
246
miR-200c
imagen42 247
miR-202
248
miR-203
249
Nombre del Precursor
Secuencia (de 5’ a 3’)* SEC ID Nº
miR-204
250
miR-205
251
miR-206-1
252
miR-206-2
253
miR-208
254
miR-210
imagen43 255
miR-211
256
miR-212
257
miR-213-2
258
miR-213
259
miR-214
imagen44 260
miR-215
261
miR-216
imagen45 262
miR-217
imagen46 263
Nombre del Precursor
Secuencia (de 5’ a 3’)* SEC ID Nº
miR-218-1
264
miR-218-2
265
miR-219
266
miR-219-1
267
miR-219-2
268
miR-220
269
miR-221
270
miR-222
imagen47 271
miR-223
272
miR-224
273
Nombre del Precursor
Secuencia (de 5’ a 3’)* SEC ID Nº
miR-294-1 (chr16)
274
miR-296
275
miR-299
276
Nombre del Precursor
Secuencia (de 5’ a 3’)* SEC ID Nº
miR-301
277
miR-302a
278
miR-302b
imagen48 279
miR-302c
280
miR-302d
281
miR-320
282
miR-321
283
miR-323
284
miR-324
285
miR-325
imagen49 286
miR-326
imagen50 287
miR-328
288
miR-330
289
miR-331
290
miR-335
291
miR-337
292
miR-338
293
miR-339
294
Nombre del Precursor
Secuencia (de 5’ a 3’)* SEC ID Nº
miR-340
295
miR-342
296
miR-345
297
miR-346
298
miR-367
299
miR-368
300
miR-369
301
miR-370
302
miR-371
303
miR-372
304
miR-373
305
miR-374
306
miR-hes1
307
miR-hes2
imagen51 308
miR-hes3
309
* Una secuencia subrayada dentro de una secuencia de precursor corresponde a un transcrito de miR procesado maduro (véase la Tabla 1b). Algunas secuencias de precursor tienen dos secuencias subrayadas que indican dos miR maduros diferentes que se obtienen a partir del mismo precursor. Todas las secuencias son humanas.
Tabla 1b -Secuencias de microARN Maduro Humano.
Nombre de miARN Maduro
Secuencia de miARN Maduro (5’ a 3’) SEC ID Nº microARN precursor correspondiente(s); véase la Tabla 1a
let-7a
ugagguaguagguuguauaguu 310 let-7a-1; let-7a-2; let-7a-3; let-7a-4
let-7b
ugagguaguagguugugugguu 311
let-7b
let-7c
ugagguaguagguuguaugguu 312
let-7c
let-7d
agagguaguagguugcauagu 313 let-7d; let-7d-vl
let-7e
ugagguaggagguuguauagu 314
let-7e
let-7f
ugagguaguagauuguauaguu 315 let-7f-1; let-7f-2-1; let-7f-2-2
let-7g
ugagguaguaguuuguacagu 316
let-7g
let-7i
ugagguaguaguuugugcu 317
let-7i
miR-1
uggaauguaaagaaguaugua 318 miR-1b; miR-1b-1; miR-1b-2
miR-7
uggaagacuagugauuuuguu 319 miR-7-1; miR-7-1a; miR-7-2; miR-7-3
miR-9
ucuuugguuaucuagcuguauga 320 miR-9-1; miR-9-2; miR-9-3
miR-9*
uaaagcuagauaaccgaaagu 321 miR-9-1; miR-9-2; miR-9-3
miR-10a
uacccuguagauccgaauuugug 322
miR-10a
miR-10b
uacccuguagaaccgaauuugu 323
miR-10b
miR-15a
uagcagcacauaaugguuugug 324 miR-15a; miR-15a-2
miR-15b
uagcagcacaucaugguuuaca 325
miR-15b
miR-16
uagcagcacguaaauauuggcg 326 miR-16-1; miR-16-2; miR-16-13
miR-17-5p
caaagugcuuacagugcagguagu 327 miR-17
miR-17-3p
acugcagugaaggcacuugu 328 miR-17
miR-18
uaaggugcaucuagugcagaua 329 miR-18; miR-18-13
miR-19a
ugugcaaaucuaugcaaaacuga 330 miR-19a; miR-19a-13
miR-19b
ugugcaaauccaugcaaaacuga 331 miR-19b-1; miR-19b-2
miR-20
uaaagugcuuauagugcaggua 332 miR-20 (miR-20a)
miR-21
uagcuuaucagacugauguuga 333 miR-21; miR-21-17
miR-22
aagcugccaguugaagaacugu 334
miR-22
miR-23a
aucacauugccagggauuucc 335
miR-23a
miR-23b
aucacauugccagggauuaccac 336
miR-23b
miR-24
uggcucaguucagcaggaacag 337 miR-24-1; miR-24-2; miR-24-19; miR24-9
miR-25
cauugcacuugucucggucuga 338
miR-25
miR-26a
uucaaguaauccaggauaggcu 339 miR-26a; miR-26a-1; miR-26a-2
miR-26b
uucaaguaauucaggauaggu 340
miR-26b
miR-27a
uucacaguggcuaaguuccgcc 341
miR-27a
miR-27b
uucacaguggcuaaguucug 342 miR-27b-1; miR-27b-2
miR-28
aaggagcucacagucuauugag 343
miR-28
miR-29a
cuagcaccaucugaaaucgguu 344 miR-29a-2; miR-29a
miR-29b
uagcaccauuugaaaucagu 345 miR-29b-1; miR-29b-2
miR-29c
uagcaccauuugaaaucgguua 346
miR-29c
miR-30a-5p
uguaaacauccucgacuggaagc 347 miR-30a
miR-30a-3p
cuuucagucggauguuugcagc 348 miR-30a
miR-30b
uguaaacauccuacacucagc 349 miR-30b-1; miR-30b-2
miR-30c
uguaaacauccuacacucucagc 350
miR-30c
miR-30d
uguaaacauccccgacuggaag 351
miR-30d
miR-30e
uguaaacauccuugacugga 352
miR-30e
miR-31
ggcaagaugcuggcauagcug 353
miR-31
miR-32
uauugcacauuacuaaguugc 354
miR-32
miR-33
gugcauuguaguugcauug 355 miR-33; miR-33b
miR-34a
uggcagugucuuagcugguugu 356
miR-34a
miR-34b
aggcagugucauuagcugauug 357
miR-34b
miR-34c
aggcaguguaguuagcugauug 358
miR-34c
miR-92
uauugcacuugucccggccugu 359 miR-92-2; miR-92-1
miR-93
aaagugcuguucgugcagguag 360 miR-93-1; miR-93-2
miR-95
uucaacggguauuuauugagca 361
miR-95
miR-96
uuuggcacuagcacauuuuugc 362
miR-96
miR-98
ugagguaguaaguuguauuguu 363
miR-98
miR-99a
aacccguagauccgaucuugug 364
miR-99a
miR-99b
cacccguagaaccgaccuugcg 365
miR-99b
miR-100
uacaguacugugauaacugaag 366
miR-100
miR-101
uacaguacugugauaacugaag 367 miR-101-1; miR-101-2
miR-103
agcagcauuguacagggcuauga 368 miR-103-1
miR-105
ucaaaugcucagacuccugu 369
miR-105
miR-106-a
aaaagugcuuacagugcagguagc 370
miR-106-a
miR-106-b
uaaagugcugacagugcagau 371
miR-106-b
miR-107
agcagcauuguacagggcuauca 372
miR-107
miR-122a
uggagugugacaaugguguuugu 373 miR-122a-1; miR-122a-2
miR-124a
uuaaggcacgcggugaaugcca 374 miR-124a-1; miR-124a-2; miR-124a-3
miR-125a
ucccugagacccuuuaaccugug 375 miR-125a-1; miR-125a-2
miR-125b
ucccugagacccuaacuuguga 376 miR-125b-1; miR-125b-2
miR-126*
cauuauuacuuuugguacgcg 377 miR-126-1; miR-126-2
miR-126
ucguaccgugaguaauaaugc 378 miR-126-1; miR-126-2
miR-127
ucggauccgucugagcuuggcu 379 miR-127-1; miR-127-2
miR-128a
ucacagugaaccggucucuuuu 380 miR-128; miR-128a
miR-128b
ucacagugaaccggucucuuuc 381
miR-128b
miR-129
cuuuuugcggucugggcuugc 382 miR-129-1; miR-129-2
miR-130a
cagugcaauguuaaaagggc 383
miR-130a
miR-130b
cagugcaaugaugaaagggcau 384
miR-130b
miR-132
uaacagucuacagccauggucg 385 miR-132-1
miR-133a
uugguccccuucaaccagcugu 386 miR-133a-1; miR-133a-2
miR-133b
uugguccccuucaaccagcua 387
miR-133b
miR-134
ugugacugguugaccagaggg 388 miR-134-1; miR-134-2
miR-135a
uauggcuuuuuauuccuauguga 389 miR-135a; miR-135a-2 (miR-135-2)
miR-135b
uauggcuuuucauuccuaugug 390
miR-135b
miR-136
acuccauuuguuuugaugaugga 391 miR-136-1; miR-136-2
miR-137
uauugcuuaagaauacgcguag 392
miR-137
miR-138
agcugguguugugaauc 393 miR-138-1; miR-138-2
miR-139
ucuacagugcacgugucu 394
miR-139
miR-140
agugguuuuacccuaugguag 395 miR-140; miR-140as; miR-140s
miR-141
aacacugucugguaaagaugg 396 miR-141-1; miR-141-2
miR-142-3p
uguaguguuuccuacuuuaugga 397 miR-142
miR-142-5p
cauaaaguagaaagcacuac 398 miR-142
miR-143
ugagaugaagcacuguagcuca 399 miR-143-1
miR-144
uacaguauagaugauguacuag 400 miR-144-1; miR-144-2
miR-145
guccaguuuucccaggaaucccuu 401 miR-145-1; miR-145-2
miR-146
ugagaacugaauuccauggguu 402 miR-146-1; miR-146-2
miR-147
guguguggaaaugcuucugc 403
miR-147
miR-148a
ucagugcacuacagaacuuugu 404 miR-148a (miR-148)
miR-148b
ucagugcaucacagaacuuugu 405
miR-148b
miR-149
ucuggcuccgugucuucacucc 406
miR-149
miR-150
ucucccaacccuuguaccagug 407 miR-150-1; miR-150-2
miR-151
acuagacugaagcuccuugagg 408
miR-151
miR-152
ucagugcaugacagaacuugg 409 miR-152-1; miR-152-2
miR-153
uugcauagucacaaaaguga 410 miR-153-1-1; miR-153-1-2; miR-1532-1; m iR-153-2-2
miR-154
uagguuauccguguugccuucg 411 miR-154-1; miR-154-2
miR-154*
aaucauacacgguugaccuauu 412 miR-154-I; miR-154-2
miR-155
uuaaugcuaaucgugauagggg 413
miR-155
miR-181a
aacauucaacgcugucggugagu 414
miR-181a
miR-181b
aacauucauugcugucgguggguu 415 miR-181b-1; miR-181b-2
miR-181c
aacauucaaccugucggugagu 416
miR-181c
miR-182
uuuggcaaugguagaacucaca 417 miR-182; miR-182as
miR-182*
ugguucuagacuugccaacua 418 miR-182; miR-182as
miR-183
uauggcacugguagaauucacug 419
miR-183
miR-184
uggacggagaacugauaagggu 420 miR-184-1; miR-184-2
miR-185
uggagagaaaggcaguuc 421 miR-185-1; miR-185-2
miR-186
caaagaauucuccuuuugggcuu 422 miR-186-1; miR-186-2
miR-187
ucgugucuuguguugcagccg 423
miR-187
miR-188
caucccuugcaugguggagggu 424
miR-188
miR-189
gugccuacugagcugauaucagu 425 miR-189-1; miR-189-2
miR-190
ugauauguuugauauauuaggu 426 miR-190-1; miR-190-2
miR-191
caacggaaucccaaaagcagcu 427 miR-191-1; miR-191-2
miR-192
cugaccuaugaauugacagcc 428
miR-192
miR-193
aacuggccuacaaagucccag 429 miR-193-1; miR-193-2
miR-194
uguaacagcaacuccaugugga 430 miR-194-1; miR-194-2
miR-195
uagcagcacagaaauauuggc 431 miR-195-1; miR-195-2
miR-196a
uagguaguuucauguuguugg 432 miR-196a; miR-196a-2 (miR19
miR-196b
uagguaguuuccuguuguugg 433
miR-196b
miR-197
uucaccaccuucuccacccagc 434
miR-197
miR-198
gguccagaggggagauagg 435
miR-198
miR-199a
cccaguguucagacuaccuguuc 436 miR-199a-1; miR-199a-2
miR-199a*
uacaguagucugcacauugguu 437 miR-199a-1; miR-199a-2; miR-199s; miR-199b
miR-199b
cccaguguuuagacuaucuguuc 438
miR-199b
miR-200a
uaacacugucugguaacgaugu 439
miR-200a
miR-200b
cucuaauacugccugguaaugaug 440
miR-200b
miR-200c
aauacugccggguaaugaugga 441
miR-200c
miR-202
agagguauagggcaugggaaga 442
miR-202
miR-203
gugaaauguuuaggaccacuag 443
miR-203
miR-204
uucccuuugucauccuaugccu 444
miR-204
miR-205
uccuucauuccaccggagucug 445
miR-205
miR-206
uggaauguaaggaagugugugg 446 miR-206-1; miR-206-2
miR-208
auaagacgagcaaaaagcuugu 447
miR-208
miR-210
cugugcgugugacagcggcug 448
miR-210
miR-211
uucccuuugucauccuucgccu 449
miR-211
miR-212
uaacagucuccagucacggcc 450
miR-212
miR-213
accaucgaccguugauuguacc 451
miR-213
miR-214
acagcaggcacagacaggcag 452
miR-214
miR-215
augaccuaugaauugacagac 453
miR-215
miR-216
uaaucucagcuggcaacugug 454
miR-216
miR-217
uacugcaucaggaacugauuggau 455
miR-217
miR-218
uugugcuugaucuaaccaugu 456 miR-218-1; miR-218-2
miR-219
ugauuguccaaacgcaauucu 457 miR-219; miR-219-1; miR-219-2
miR-220
ccacaccguaucugacacuuu 458
miR-220
miR-221
agcuacauugucugcuggguuuc 459
miR-221
miR-222
agcuacaucuggcuacugggucuc 460
miR-222
miR-223
ugucaguuugucaaauacccc 461
miR-223
miR-224
caagucacuagugguuccguuua 462
miR-224
miR-296
agggcccccccucaauccugu 463
miR-296
miR-299
ugguuuaccgucccacauacau 464
miR-299
miR-301
cagugcaauaguauugucaaagc 465
miR-301
miR-302a
uaagugcuuccauguuuugguga 466
miR-302a
miR-302b*
acuuuaacauggaagugcuuucu 467 miR-302b
miR-302b
uaagugcuuccauguuuuaguag 468
miR-302b
miR-302c*
uuuaacauggggguaccugcug 469 miR-302c
miR-302c
uaagugcuuccauguuucagugg 470
miR-302c
miR-302d
uaagugcuuccauguuugagugu 471
miR-302d
miR-320
aaaagcuggguugagagggcgaa 472
miR-320
miR-321
uaagccagggauuguggguuc 473
miR-321
miR-323
gcacauuacacggucgaccucu 474
miR-323
miR-324-5p
cgcauccccuagggcauuggugu 475 miR-324
miR-324-3p
ccacugccccaggugcugcugg 476 miR-324
miR-325
ccuaguagguguccaguaagu 477
miR-325
miR-326
ccucugggcccuuccuccag 478
miR-326
miR-328
cuggcccucucugcccuuccgu 479
miR-328
miR-330
gcaaagcacacggccugcagaga 480
miR-330
miR-331
gccccugggccuauccuagaa 481
miR-331
miR-335
ucaagagcaauaacgaaaaaugu 482
miR-335
miR-337
uccagcuccuauaugaugccuuu 483
miR-337
miR-338
uccagcaucagugauuuuguuga 484
miR-338
miR-339
ucccuguccuccaggagcuca 485
miR-339
miR-340
uccgucucaguuacuuuauagcc 486
miR-340
miR-342
ucucacacagaaaucgcacccguc 487
miR-342
miR-345
ugcugacuccuaguccagggc 488
miR-345
miR-346
ugucugcccgcaugccugccucu 489
miR-346
miR-367
aauugcacuuuagcaaugguga 490
miR-367
miR-368
acauagaggaaauuccacguuu 491
miR-368
miR-369
aauaauacaugguugaucuuu 492
miR-369
miR-370
gccugcugggguggaaccugg 493
miR-370
miR-371
gugccgccaucuuuugagugu 494
miR-371
miR-372
aaagugcugcgacauuugagcgu 495
miR-372
imagen52
imagen53
imagen54
imagen55
imagen56
imagen57
imagen58
imagen59
imagen60
imagen61
imagen62
imagen63
imagen64
imagen65
imagen66
imagen67
imagen68
imagen69
imagen70
imagen71
imagen72
imagen73

Claims (1)

  1. imagen1
ES12165734.0T 2006-01-05 2007-01-03 Procedimientos basados en los microARN para el diagnóstico, pronóstico y tratamiento del cáncer de pulmón Active ES2554531T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75640006P 2006-01-05 2006-01-05
US756400P 2006-01-05

Publications (1)

Publication Number Publication Date
ES2554531T3 true ES2554531T3 (es) 2015-12-21

Family

ID=38256884

Family Applications (4)

Application Number Title Priority Date Filing Date
ES07717734T Active ES2429404T3 (es) 2006-01-05 2007-01-03 Procedimientos basados en los microARN para el diagnóstico y el pronóstico del cáncer de pulmón
ES12165734.0T Active ES2554531T3 (es) 2006-01-05 2007-01-03 Procedimientos basados en los microARN para el diagnóstico, pronóstico y tratamiento del cáncer de pulmón
ES12165740.7T Active ES2553442T3 (es) 2006-01-05 2007-01-03 Procedimientos basados en los microARN para el diagnóstico, pronóstico y tratamiento del cáncer de pulmón
ES12165748.0T Active ES2536438T3 (es) 2006-01-05 2007-01-03 Métodos y composiciones basados en los microARN para el diagnóstico, pronóstico y tratamiento del cáncer de pulmón

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES07717734T Active ES2429404T3 (es) 2006-01-05 2007-01-03 Procedimientos basados en los microARN para el diagnóstico y el pronóstico del cáncer de pulmón

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES12165740.7T Active ES2553442T3 (es) 2006-01-05 2007-01-03 Procedimientos basados en los microARN para el diagnóstico, pronóstico y tratamiento del cáncer de pulmón
ES12165748.0T Active ES2536438T3 (es) 2006-01-05 2007-01-03 Métodos y composiciones basados en los microARN para el diagnóstico, pronóstico y tratamiento del cáncer de pulmón

Country Status (8)

Country Link
US (3) US7943318B2 (es)
EP (4) EP2514434B1 (es)
JP (1) JP5451077B2 (es)
CN (3) CN101400361B (es)
AU (1) AU2007205234B2 (es)
CA (1) CA2633674A1 (es)
ES (4) ES2429404T3 (es)
WO (1) WO2007081720A2 (es)

Families Citing this family (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005078139A2 (en) 2004-02-09 2005-08-25 Thomas Jefferson University DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES
EP2290072B1 (en) 2004-05-28 2014-12-17 Asuragen, Inc. Methods and compositions involving microRNA
ES2534304T3 (es) 2004-11-12 2015-04-21 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
CN101341259B (zh) 2005-08-01 2011-12-21 俄亥俄州立大学研究基金会 用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物
EP1937280B1 (en) 2005-09-12 2014-08-27 The Ohio State University Research Foundation Compositions for the therapy of bcl2-associated cancers
JP5490413B2 (ja) 2006-01-05 2014-05-14 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 膵内分泌腫瘍及び膵腺房腫瘍におけるマイクロｒｎａ発現異常
ES2429404T3 (es) 2006-01-05 2013-11-14 The Ohio State University Research Foundation Procedimientos basados en los microARN para el diagnóstico y el pronóstico del cáncer de pulmón
EP2487261B1 (en) 2006-01-05 2015-07-01 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
CA2646051A1 (en) * 2006-03-20 2007-09-27 Carlo M. Croce Microrna fingerprints during human megakaryocytopoiesis
US8207325B2 (en) * 2006-04-03 2012-06-26 Univ. of Copenhagen MicroRNA biomarkers for human breast and lung cancer
WO2008008430A2 (en) 2006-07-13 2008-01-17 The Ohio State University Research Foundation Micro-rna-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases
US8071292B2 (en) 2006-09-19 2011-12-06 The Ohio State University Research Foundation Leukemia diagnostic methods
WO2008036765A2 (en) * 2006-09-19 2008-03-27 Asuragen, Inc. Micrornas differentially expressed in pancreatic diseases and uses thereof
EP2087135B8 (en) 2006-11-01 2013-07-24 The Ohio State University Research Foundation Microrna expression signature for predicting survival and metastases in hepatocellular carcinoma
US8338109B2 (en) 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
CN103555825B (zh) 2007-01-31 2015-09-30 俄亥俄州立大学研究基金会 用于急性髓细胞白血病(aml)的诊断、预后和治疗的基于微rna的方法和组合物
WO2008136971A1 (en) * 2007-04-30 2008-11-13 The Ohio State University Research Foundation Methods for differentiating pancreatic cancer from normal pancreatic function and/or chronic pancreatitis
ES2527648T3 (es) 2007-06-08 2015-01-28 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Métodos para determinar el subtipo de carcinoma hepatocelular
US8053186B2 (en) 2007-06-15 2011-11-08 The Ohio State University Research Foundation Oncogenic ALL-1 fusion proteins for targeting Drosha-mediated microRNA processing
US8440636B2 (en) 2007-07-31 2013-05-14 The Board Of Regents, The University Of Texas System Micro-RNA family that modulates fibrosis and uses thereof
CA2695184A1 (en) * 2007-07-31 2009-02-05 The Ohio State University Research Foundation Methods for reverting methylation by targeting dnmt3a and dnmt3b
ES2570359T3 (es) 2007-08-03 2016-05-18 Univ Ohio State Res Found Regiones ultraconservadas que codifican ARNnc
EP2188395A4 (en) * 2007-08-17 2010-10-13 Catalyst Assets Llc USE OF MICRO-RNA ASSOCIATED WITH CANCER OF THE HUMAN BLADDER FOR DIAGNOSIS AND PROGNOSIS
EP3028708A1 (en) 2007-08-22 2016-06-08 The Ohio State University Research Foundation Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias
WO2009024790A1 (en) * 2007-08-23 2009-02-26 Isis Innovation Limited Method and kit for the prognosis of cancer by determining the level of mirna-210
EP2198050A1 (en) 2007-09-14 2010-06-23 Asuragen, INC. Micrornas differentially expressed in cervical cancer and uses thereof
WO2009044899A1 (ja) * 2007-10-03 2009-04-09 Kyowa Hakko Kirin Co., Ltd. 細胞の増殖を制御する核酸
CA2702241A1 (en) * 2007-10-11 2009-04-16 The Ohio State University Research Foundation Methods and compositions for the diagnosis and treatment of esophageal adenocarcinomas
WO2009052386A1 (en) * 2007-10-18 2009-04-23 Asuragen, Inc. Micrornas differentially expressed in lung diseases and uses thereof
JP2011504093A (ja) 2007-10-26 2011-02-03 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 脆弱性ヒスチジン三連構造（ｆｈｉｔ）相互作用を同定するための方法およびその使用
CN101878313A (zh) * 2007-10-30 2010-11-03 维里德克斯有限责任公司 预测鳞状细胞肺癌的方法
US20100323357A1 (en) * 2007-11-30 2010-12-23 The Ohio State University Research Foundation MicroRNA Expression Profiling and Targeting in Peripheral Blood in Lung Cancer
US8071562B2 (en) 2007-12-01 2011-12-06 Mirna Therapeutics, Inc. MiR-124 regulated genes and pathways as targets for therapeutic intervention
JP5116026B2 (ja) 2008-01-23 2013-01-09 富士フイルム株式会社 癌の検出方法および癌抑制剤
AU2009209415A1 (en) * 2008-02-01 2009-08-06 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions relating to carcinoma stem cells
EP3064584A3 (en) * 2008-02-28 2016-12-07 The Ohio State University Research Foundation Micro rna-based methods and compositions for the diagnosis, prognosis and treatmentof gastric cancer
US8258111B2 (en) 2008-05-08 2012-09-04 The Johns Hopkins University Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
EP2806054A1 (en) 2008-05-28 2014-11-26 Genomedx Biosciences Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
EP2294218A2 (en) * 2008-06-02 2011-03-16 New York University Compositions and methods for diagnosis, prognosis and treatment of mesothelioma
WO2009149318A2 (en) * 2008-06-05 2009-12-10 Research Foundation Of State University Of New York Mirnas as therapeutic targets in cancer
CN102149827B (zh) 2008-06-11 2014-08-20 由卫生与公众服务部代表的美利坚合众国政府 MiR-26家族作为肝细胞癌和对治疗的应答性的预测性标志物的用途
WO2009153775A2 (en) * 2008-06-17 2009-12-23 Rosetta Genomics Ltd. Methods for distinguishing between specific types of lung cancers
EP2145964A1 (en) * 2008-07-17 2010-01-20 Universität Zu Köln A method for lung cancer early detection and prognosis
BRPI0919882A8 (pt) * 2008-10-30 2017-09-19 Caris Life Sciences Luxembourg Holdings Métodos para avaliar padrões de rna
CN107254538A (zh) * 2008-11-12 2017-10-17 卡里斯生命科学瑞士控股有限责任公司 使用外来体来确定表现型的方法和系统
CN101475984A (zh) * 2008-12-15 2009-07-08 江苏命码生物科技有限公司 一种非小细胞肺癌检测标记物及其检测方法、相关生物芯片和试剂盒
US20100240049A1 (en) 2009-01-16 2010-09-23 Cepheid Methods of Detecting Cervical Cancer
WO2010084488A1 (en) 2009-01-20 2010-07-29 Ramot At Tel-Aviv University Ltd. Mir-21 promoter driven targeted cancer therapy
WO2010093907A2 (en) * 2009-02-13 2010-08-19 The Board Of Regents Of The University Of Texas System An assay for the detection of recurrence in breast cancer using the novel tumor suppressor dear1
CN102272330B (zh) * 2009-02-23 2014-04-23 博奥生物有限公司 用于肺癌诊断、预后和提高生存率的试剂盒
EP2628803A3 (en) * 2009-02-25 2014-01-01 Cepheid Methods of detecting lung cancer
WO2010099161A1 (en) * 2009-02-26 2010-09-02 The Ohio State University Research Foundation Micrornas in never-smokers and related materials and methods
IT1398768B1 (it) * 2009-03-24 2013-03-18 Zollo Uso di microrna-199b-5p in campo medico e diagnostico.
AU2010234806B2 (en) 2009-03-31 2014-05-22 The United States Of America As Represented By The Secretary Department Of Health And Human Services Differentially expressed microRNAs as biomarkers for the diagnosis and treatment of Sjogren's syndrome
US20110105585A1 (en) * 2009-04-23 2011-05-05 Northwestern University METHODS FOR DIAGNOSING AND TREATING SQUAMOUS CELL CARCINOMA UTILIZING miRNA-205 AND INHIBITORS THEREOF
EP2336353A1 (en) * 2009-12-17 2011-06-22 febit holding GmbH miRNA fingerprints in the diagnosis of diseases
JP5546064B2 (ja) * 2009-07-09 2014-07-09 中国医学科学院▲腫▼瘤研究所 肺がん予後および薬物調製における２つのマイクロＲＮＡｓの使用
PL212748B1 (pl) * 2009-07-30 2012-11-30 Gdanski Univ Medyczny Sposób okreslania ryzyka odleglego nawrotu niedrobnokomórkowego raka pluca u chorych w stopniu I-III A zaawansowania leczonych chirurgicznie
US8911940B2 (en) 2009-07-31 2014-12-16 The Translational Genomics Research Institute Methods of assessing a risk of cancer progression
EP2470897A4 (en) * 2009-08-28 2013-05-29 Asuragen Inc MICRO-RNA BIOMARKERS OF PULMONARY DISEASE
CN102018963B (zh) * 2009-09-11 2013-03-13 中国科学院上海生命科学研究院 调节RANTES表达的miR-125a、其组合物及其用途
EP2486929B1 (en) * 2009-10-01 2017-03-15 National Cancer Center Therapeutic agent for tumor
SG2014010698A (en) * 2009-11-02 2014-05-29 Agency Science Tech & Res Methods of monitoring cellular states
JP5960060B2 (ja) 2009-11-23 2016-08-02 ジ・オハイオ・ステート・ユニバーシティ 腫瘍細胞の増殖、遊走および浸潤に影響を与えるために有用な物質および方法
CN102080083B (zh) * 2009-12-01 2013-02-27 中国科学院上海药物研究所 人miR-149反义核酸及其应用
WO2011084815A1 (en) * 2009-12-21 2011-07-14 Board Of Trustees Of Southern Illinois University Inhibition of ubc9-mediated cancer cell invasion and metastasis
CN102782155B (zh) * 2009-12-24 2016-05-04 复旦大学 用于肺癌的血浆中微rna表达谱分析的组合物和方法
WO2011076145A1 (en) * 2009-12-24 2011-06-30 Fudan University Tissue-based micro-rna methods for diagnosis of different subtypes of lung cancer
CN102770561B (zh) * 2009-12-24 2015-05-06 复旦大学 用于诊断不同亚型肺癌的基于组织的微-rna方法
KR20130056855A (ko) 2010-03-01 2013-05-30 카리스 라이프 사이언스 룩셈부르크 홀딩스 치료진단용 생물학적 지표들
WO2011115884A1 (en) * 2010-03-18 2011-09-22 Centocor Ortho Biotech Inc. Diagnostic for lung cancer using mirna
JP5931050B2 (ja) * 2010-03-26 2016-06-08 ジ・オハイオ・ステート・ユニバーシティ ｍｉＲ−１５５によるミスマッチ修復およびゲノム安定性の調節に関連する材料および方法
JPWO2011125245A1 (ja) * 2010-04-05 2013-07-08 公益財団法人がん研究会 ｍｉＲＮＡを用いた小細胞肺癌の予後予測方法、小細胞肺癌治療方法、小細胞肺癌予後改善方法、及び小細胞肺癌治療剤のスクリーニング方法
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
WO2011150855A1 (en) * 2010-06-04 2011-12-08 Fudan University Micro-rna biomarkers and methods for diagnosis of early colorectal carcinoma and high-grade adenoma
WO2011156777A1 (en) 2010-06-10 2011-12-15 Fred Hutchinson Cancer Research Center Use of blood mir-210 for cancer prognosis
EP3369817A1 (en) 2010-07-06 2018-09-05 InteRNA Technologies B.V. Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma , or in diseases or conditions with activated braf pathway
JP5775517B2 (ja) 2010-07-08 2015-09-09 武田薬品工業株式会社 糖尿病の予防・治療剤
CA2816603A1 (en) 2010-11-12 2012-05-18 The Ohio State University Research Foundation Materials and methods related to microrna-21, mismatch repair, and colorectal cancer
EP2640368B1 (en) 2010-11-15 2020-12-30 The Ohio State University Research Foundation Controlled release mucoadhesive systems
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
EP2505663A1 (en) 2011-03-30 2012-10-03 IFOM Fondazione Istituto Firc di Oncologia Molecolare A method to identify asymptomatic high-risk individuals with early stage lung cancer by means of detecting miRNAs in biologic fluids
CN102140467B (zh) * 2010-12-30 2013-05-15 苏州吉玛基因股份有限公司 人miR-365反义核酸及其应用
CN102140466B (zh) * 2010-12-30 2013-03-27 苏州吉玛基因股份有限公司 人miR-1825反义核酸及其应用
EP2474617A1 (en) 2011-01-11 2012-07-11 InteRNA Technologies BV Mir for treating neo-angiogenesis
WO2012097047A1 (en) * 2011-01-11 2012-07-19 The Ohio State University Research Foundation Methods to identify chronic lymphocytic leukemia disease progression
CN102586412B (zh) * 2011-01-18 2015-05-20 上海市第一人民医院 一种MicroRNA特异表达谱及其应用
AU2012211272A1 (en) 2011-01-26 2013-08-15 Cepheid Methods of detecting lung cancer
MX2013008944A (es) 2011-02-03 2014-01-08 Mirna Therapeutics Inc Mimeticos sinteticos de mir-124.
IT1403685B1 (it) * 2011-02-07 2013-10-31 Fond Irccs Istituto Naz Dei Tumori Procedimento ed apparecchiatura per identificare individui a rischio di tumore polmonare e/o per diagnosticare un tumore polmonare, nonche' composizione e metodo per ridurre o eliminare il rischio di tumore polmonare.
BR112014003877A2 (pt) 2011-02-07 2017-06-13 Biomirna Holdings Ltd biomarcadores de micro-rna e métodos de uso dos mesmos
IT1406866B1 (it) * 2011-02-07 2014-03-14 Fond Irccs Istituto Naz Dei Tumori Procedimento ed apparecchiatura per identificare individui a rischio di tumore polmonare e/o per diagnosticare un tumore polmonare, nonché composizione e metodo per ridurre o eliminare il rischio di tumore polmonare
EP2683387A4 (en) 2011-03-07 2014-09-03 Univ Ohio State MUTATOR ACTIVITY INDUCED BY MICRORNA-155 (miR-155) LINKS INFLAMMATION AND CANCER
JP2014509522A (ja) * 2011-03-28 2014-04-21 ロゼッタ ゲノミクス リミテッド 肺癌を分類するための方法
US9644241B2 (en) 2011-09-13 2017-05-09 Interpace Diagnostics, Llc Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease
CN104364390B (zh) 2011-10-14 2016-08-24 俄亥俄州立大学 与卵巢癌相关的方法和材料
WO2013090620A1 (en) 2011-12-13 2013-06-20 Genomedx Biosciences, Inc. Cancer diagnostics using non-coding transcripts
EP2790735A4 (en) 2011-12-13 2015-12-09 Ohio State Innovation Foundation METHODS AND COMPOSITIONS RELATING TO MIR-21 AND MIR-29A, EXOSOME INHIBITION, AND CANCER METASTASIS
CN102533984A (zh) * 2011-12-19 2012-07-04 苏州福英基因科技有限公司 癌症病理演变前期microrna17-3p水平原位杂交检测试剂盒及检测方法和应用
CN102533983A (zh) * 2011-12-19 2012-07-04 苏州福英基因科技有限公司 癌症病理演变前期microrna-330水平原位杂交检测试剂盒及检测方法和应用
ITRM20110685A1 (it) 2011-12-23 2013-06-24 Internat Ct For Genetic En Gineering And Microrna per la rigenerazione cardiaca attraverso l induzione della proliferazione dei miociti cardiaci
CN102559884A (zh) * 2011-12-27 2012-07-11 芮屈生物技术（上海）有限公司 各种癌症病理演变前期let-7mirna水平原位杂交检测试剂盒及检测方法和应用
CN104685065B (zh) 2012-01-20 2017-02-22 俄亥俄州立大学 浸润性和预后的乳腺癌生物标志物标签
CN102776194A (zh) * 2012-07-20 2012-11-14 苏州大学 微小rna用于调控pten基因表达
US10196662B2 (en) * 2012-08-10 2019-02-05 Mello Biotechnology, Inc. Composition for producing microRNA precursors as drugs for enhancing wound healing and production method of the microRNA precursors
ES2945036T3 (es) 2012-08-16 2023-06-28 Veracyte Sd Inc Pronóstico del cáncer de próstata mediante biomarcadores
KR101501826B1 (ko) * 2013-04-05 2015-03-13 연세대학교 산학협력단 위암에 대한 예후 예측 모형의 제조방법
CN103285406B (zh) * 2013-05-27 2015-05-13 哈尔滨医科大学 microRNA-203及其拟似物在制备防治肥胖、血脂异常及其并发症药物中的应用
CN103751801A (zh) * 2013-09-10 2014-04-30 上海大学 非小细胞肺癌中miR-143基因的应用
PL405648A1 (pl) 2013-10-15 2015-04-27 Warszawski Uniwersytet Medyczny Sposób diagnozowania raka watrobowokomórkowego, zastosowanie markera mikroRNA do diagnozowania zmiany chorobowej w obrębie wątroby, oceny stopnia zaawansowania choroby oraz oceny podatności pacjenta i/lub choroby na zaproponowane leczenie oraz zawierający takie markery zestaw diagnostyczny
PL406033A1 (pl) 2013-11-14 2015-05-25 Warszawski Uniwersytet Medyczny Sposób diagnozowania raka brodawkowatego tarczycy, zastosowanie markera mikroRNA do diagnozowania nowotworu tarczycy, oceny stopnia zaawansowania choroby oraz oceny podatności pacjenta i/lub choroby na zaproponowane leczenie oraz zawierający takie markery zestaw diagnostyczny
CN103948926A (zh) * 2014-03-24 2014-07-30 江苏大学 miR-9抑制剂在制备用于抑制肿瘤生长药物中的用途
CN104031987B (zh) * 2014-05-12 2016-08-31 贵州省人民医院 miRNA在心肌纤维化疾病治疗中的应用
KR102511402B1 (ko) 2014-06-18 2023-03-17 국립연구개발법인 고쿠리츠간켄큐센터 폐암의 검출 키트 또는 디바이스 및 검출 방법
CN104152452B (zh) * 2014-08-19 2016-08-24 中国人民解放军总医院第一附属医院 一种与肝癌相关的血液miRNA标志物及其应用
US20160070852A1 (en) * 2014-09-04 2016-03-10 National Taiwan University Prognosis prediction for acute myeloid leukemia by a 3-microrna scoring method
CN104911248A (zh) * 2014-12-18 2015-09-16 南京大学 一种用于ii、iii期结直肠癌诊断及预后的微小核糖核酸组合及其应用
CN104726448B (zh) * 2014-12-29 2018-03-30 常州杰傲病理诊断技术有限公司 一种用于肺癌组织分型的miRNA标志物及应用
US20180142303A1 (en) * 2015-05-19 2018-05-24 The Wistar Institute Of Anatomy And Biology Methods and compositions for diagnosing or detecting lung cancers
EP3303590A4 (en) 2015-06-05 2019-01-02 Miragen Therapeutics, Inc. Mir-155 inhibitors for treating cutaneous t cell lymphoma (ctcl)
US11925628B2 (en) * 2015-06-30 2024-03-12 Shanghai Jiao Tong University Applications for nicardipine in preparing anti-lung cancer products
CN105457041B (zh) * 2015-12-09 2020-09-08 上海大学 miR-26a在非小细胞肺癌中的应用
CN105561339B (zh) * 2015-12-21 2019-02-22 江苏省人民医院 一种miRNA的组合制备抗非小细胞肺癌药物中的应用
CN105726559B (zh) * 2016-03-21 2018-12-18 南通大学 miRNA-17-3p和miRNA-19b-1组合物及其应用
ES2646826B1 (es) * 2016-05-13 2018-10-01 Servicio Andaluz De Salud MicroARNs como biomarcadores para el diagnóstico del cáncer de pulmón
JP2019517471A (ja) * 2016-05-27 2019-06-24 リン、シー−ランLIN, Shi−Lung Ｍｉｒ−３０２前駆体を抗癌薬物としてヒト肺癌を治療するために用いる組成物及び方法
CN106055921A (zh) * 2016-05-27 2016-10-26 华中农业大学 基于基因表达和药物靶标的药物活性预测与筛选方法
CN109789156B (zh) * 2016-06-14 2022-06-07 新加坡科技研究局 miR-198在治疗和诊断皮肤鳞状细胞癌中的用途
CN105950753B (zh) * 2016-06-16 2019-10-01 朱伟 一种与肺腺癌辅助诊断相关的血浆miRNA标志物及其应用
KR101888744B1 (ko) 2016-08-02 2018-10-04 연세대학교 산학협력단 Alk 저해제에 내성을 획득한 eml4-alk 양성 비소세포폐암의 치료를 위한 약물 선택의 정보 제공 방법
AU2017315425B2 (en) 2016-08-24 2023-11-09 The Regents Of The University Of Michigan Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
US10738363B2 (en) 2016-08-31 2020-08-11 National Central University Analyzer and analytical method for predicting prognosis of cancer radiotherapy
US11584932B2 (en) 2016-11-01 2023-02-21 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
EP3545091A1 (en) * 2016-11-25 2019-10-02 Centre National De La Recherche Scientifique Agents for the treatment of patients with nsclc and methods to predict response
CN107058480B (zh) * 2016-12-14 2018-07-13 河北医科大学第四医院（河北省肿瘤医院） 用于诊断肺腺癌的长链非编码rna标志物
EP3571322B9 (en) 2017-01-20 2023-10-04 VERACYTE SD, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
WO2018136919A2 (en) 2017-01-23 2018-07-26 Trustees Of Boston University Methods relating to lung cancer
CN106755521B (zh) * 2017-02-20 2019-03-08 南京盖斯夫医药科技有限公司 血浆microRNAs用于制备筛查诊断女性群体中肺腺癌患者的诊断试剂的用途
CA3055925A1 (en) 2017-03-09 2018-09-13 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
US11078542B2 (en) 2017-05-12 2021-08-03 Decipher Biosciences, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness
KR20250006333A (ko) * 2017-06-29 2025-01-10 도레이 카부시키가이샤 폐암의 검출을 위한 키트, 디바이스 및 방법
US12497660B2 (en) 2017-08-04 2025-12-16 Veracyte SD, Inc. Use of immune cell-specific gene expression for prognosis of prostate cancer and prediction of responsiveness to radiation therapy
CN107365852B (zh) * 2017-08-14 2021-08-13 江苏为真生物医药技术股份有限公司 血清外泌体中肺癌相关microRNA分子标记的应用及其检测试剂盒
CN107475388B (zh) * 2017-08-22 2020-05-19 深圳市恩普电子技术有限公司 鼻咽癌相关的miRNA作为生物标志物的应用及鼻咽癌检测试剂盒
CN108096266A (zh) * 2017-11-30 2018-06-01 佛山英特医药科技有限公司 miRNA-370在抗肿瘤作用、实施方法及用途
CN108841962B (zh) * 2018-08-01 2021-11-19 博奥生物集团有限公司 一种非小细胞肺癌检测试剂盒及其应用
CN109207599A (zh) * 2018-11-12 2019-01-15 觅瑞（杭州）生物科技有限公司 一种用于非小细胞肺癌诊断的外周血miRNA标志物
JP2020092688A (ja) * 2018-12-12 2020-06-18 国立大学法人東海国立大学機構 マイクロｒｎａを含む体液抽出物
CN109385478B (zh) * 2018-12-20 2021-08-03 首都医科大学附属北京朝阳医院 检测19-gcs的基因标记在制备用于诊断早期肺腺癌预后的产品中的应用
CN111218513B (zh) * 2020-04-24 2020-08-14 上海思路迪医学检验所有限公司 一种用于肺癌早期诊断的外周血胞外囊泡microRNA生物标志物及其用途
WO2021262919A2 (en) 2020-06-26 2021-12-30 The Research Foundation For The State University Of New York 5-halouracil-modified micrornas and their use in the treatment of cancer
JP2023545017A (ja) * 2020-10-02 2023-10-26 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム 肺がんの検出及び治療のための方法
WO2023074135A1 (ja) * 2021-11-01 2023-05-04 国立研究開発法人国立がん研究センター 肺がんの予後の判定を補助する方法及び試薬キット
CN115896291A (zh) * 2022-12-05 2023-04-04 四川省肿瘤医院 一种用于诊断肺腺癌的标志物及应用
CN116585342B (zh) * 2023-05-23 2024-08-16 源生生物科技(青岛)有限责任公司 包含miRNA的活性成分及其应用
CN117286252B (zh) * 2023-11-16 2024-04-09 上海交通大学医学院 一种诊断和预后评估肺癌的生物标志物组合及其应用
CN118236389B (zh) * 2024-05-28 2024-09-24 南京晖丽生物科技有限公司 miR-3120在制备预防及治疗肿瘤及肿瘤恶液质的药物组合物中的应用

Family Cites Families (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4172124A (en) 1978-04-28 1979-10-23 The Wistar Institute Method of producing tumor antibodies
US4608337A (en) 1980-11-07 1986-08-26 The Wistar Institute Human hybridomas and the production of human monoclonal antibodies by human hybridomas
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4701409A (en) 1984-11-15 1987-10-20 The Wistar Institute Detection of B-cell neoplasms
US4693975A (en) 1984-11-20 1987-09-15 The Wistar Institute Human hybridroma fusion partner for production of human monoclonal antibodies
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5015568A (en) 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans
US5202429A (en) 1986-07-09 1993-04-13 The Wistar Institute DNA molecules having human BCL-2 gene sequences
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4712124A (en) * 1986-12-22 1987-12-08 North American Philips Corporation Complementary lateral insulated gate rectifiers with matched "on" resistances
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP0341904B1 (en) 1988-05-09 1995-03-29 Temple University of the Commonwealth System of Higher Education Method for predicting the effectiveness of antineoplastic therapy in individual patients
US5198338A (en) 1989-05-31 1993-03-30 Temple University Molecular probing for human t-cell leukemia and lymphoma
US5149628A (en) 1989-11-15 1992-09-22 Temple University Methods for detecting bcl-3 gene in human leukemias
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
WO1993012136A1 (en) 1991-12-11 1993-06-24 Thomas Jefferson University Detection and treatment of acute leukemias resulting from chromosome abnormalities in the all-1 region
US5633135A (en) 1991-12-11 1997-05-27 Thomas Jefferson University Chimeric nucleic acids and proteins resulting from ALL-1 region chromosome abnormalities
US6040140A (en) 1991-12-11 2000-03-21 Thomas Jefferson University Methods for screening and treating leukemias resulting from all-1 region chromosome abnormalities
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
DK0667920T3 (da) 1992-10-29 2003-04-14 Univ Jefferson Fremgangsmåder til påvisning af prostatacancermetastase
US5674682A (en) 1992-10-29 1997-10-07 Thomas Jefferson University Nucleic acid primers for detecting micrometastasis of prostate cancer
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US7175995B1 (en) 1994-10-27 2007-02-13 Thomas Jefferson University TCL-1 protein and related methods
US5985598A (en) 1994-10-27 1999-11-16 Thomas Jefferson University TCL-1 gene and protein and related methods and compositions
US5695944A (en) 1995-05-05 1997-12-09 Thomas Jefferson University Modulation of bcl-2 phosphorylation
US5567586A (en) 1995-05-18 1996-10-22 Thomas Jefferson University Methods of indentifying solid tumors with chromosome abnormalities in the ALL-1 region
US5928884A (en) 1996-02-09 1999-07-27 Croce; Carlo M. FHIT proteins and nucleic acids and methods based thereon
US6242212B1 (en) 1996-02-09 2001-06-05 Thomas Jefferson University Fragile histidine triad (FHIT) nucleic acids and methods of producing FHIT proteins
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
US6187536B1 (en) 1997-02-18 2001-02-13 Thomas Jefferson University Methods of identifying and detecting pancreatic cancer
AU6951098A (en) 1997-04-04 1998-10-30 The Texas A & M University System Noninvasive detection of colonic biomarkers using fecal messenger rna
CA2335315A1 (en) 1998-07-20 2000-01-27 Thomas Jefferson University Nitrilase homologs
US6255293B1 (en) 1998-07-24 2001-07-03 Yeda Research And Development Co., Ltd. Prevention of metastasis with 5-aza-2′-deoxycytidine
US7141417B1 (en) 1999-02-25 2006-11-28 Thomas Jefferson University Compositions, kits, and methods relating to the human FEZ1 gene, a novel tumor suppressor gene
JP2003519463A (ja) 1999-03-15 2003-06-24 トーマス・ジェファーソン・ユニバーシティー ＴＣＬ−１ｂ遺伝子、蛋白質、それらに関連した方法およびそれらに関連する物質
US7163801B2 (en) 1999-09-01 2007-01-16 The Burnham Institute Methods for determining the prognosis for cancer patients using tucan
SE0000522D0 (sv) * 2000-02-17 2000-02-17 Astrazeneca Ab Mixing apparatus
US6891031B2 (en) 2000-02-18 2005-05-10 The Regents Of The University Of California Coordinate cytokine regulatory sequences
WO2001068666A1 (en) 2000-03-14 2001-09-20 Thomas Jefferson University Tcl1 enhances akt kinase activity and mediates its nuclear translocation
PT1309726E (pt) 2000-03-30 2010-03-08 Whitehead Biomedical Inst Mediadores de interferência por rna específicos de sequência de rna
EP1276879A4 (en) 2000-04-11 2004-12-22 Univ Jefferson MUIR-TORRE-LIKE SYNDROME IN Fhit-DEFECTIVE MICE
US20020086331A1 (en) 2000-05-16 2002-07-04 Carlo Croce Crystal structure of worm NitFhit reveals that a Nit tetramer binds two Fhit dimers
US7060811B2 (en) 2000-10-13 2006-06-13 Board Of Regents, The University Of Texas System WWOX: a tumor suppressor gene mutated in multiple cancers
US20020173478A1 (en) 2000-11-14 2002-11-21 The Trustees Of The University Of Pennsylvania Post-transcriptional gene silencing by RNAi in mammalian cells
US20040033502A1 (en) 2001-03-28 2004-02-19 Amanda Williams Gene expression profiles in esophageal tissue
US20050176025A1 (en) 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA)
JP4371812B2 (ja) 2001-09-28 2009-11-25 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ マイクロｒｎａ分子
US7371736B2 (en) 2001-11-07 2008-05-13 The Board Of Trustees Of The University Of Arkansas Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss
GB0128898D0 (en) 2001-12-03 2002-01-23 Biotech Res Ventures Pte Ltd Materials and methods relating to the stabilization and activation of a tumour suppressor protein
WO2003076424A1 (en) 2002-03-08 2003-09-18 Eisai Co. Ltd. Macrocyclic compounds useful as pharmaceuticals
WO2003086445A1 (en) 2002-04-08 2003-10-23 Ciphergen Biosystems, Inc. Serum biomarkers in hepatocellular carcinoma
WO2003092370A1 (en) 2002-04-29 2003-11-13 Thomas Jefferson University Human chronic lymphocytic leukemia modeled in mouse by targeted tcl1 expression
EP1530418A4 (en) 2002-05-31 2005-10-12 Univ Leland Stanford Junior METHOD FOR IDENTIFYING AND INSULATING STEM CELLS AND CANCER STAMPS
AU2003253618B2 (en) 2002-05-31 2007-11-15 The Regents Of The University Of California Method for efficient RNA interference in mammalian cells
AU2003253860A1 (en) * 2002-07-10 2004-01-23 The Regents Of The University Of Michigan Expression profile of lung cancer
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
US20050260639A1 (en) 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Method for diagnosing pancreatic cancer
EP1581621A4 (en) 2002-10-11 2006-07-05 Univ Jefferson NEW TUMORSUPPRESSORGEN AND COMPOSITIONS AND METHOD FOR THE PRODUCTION AND USE THEREOF
US20050266443A1 (en) 2002-10-11 2005-12-01 Thomas Jefferson University Novel tumor suppressor gene and compositions and methods for making and using the same
CA2504605C (en) 2002-11-13 2016-01-19 Thomas Jefferson University Treatment of chronic lymphocytic leukemia and prostate cancer with microrna mir15
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
WO2004071464A2 (en) 2003-02-12 2004-08-26 Johns Hopkins University School Of Medicine Diagnostic application of differentially-expressed genes in lympho-hematopoietic stem cells
WO2004079013A1 (en) 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
US7183384B2 (en) 2003-03-06 2007-02-27 A & G Pharmaceutical, Inc. Monoclonal antibody 7H11 reactive with human cancer
AU2003286741A1 (en) 2003-05-02 2004-11-26 Thomas Jefferson University Methods and compositions for diagnosis and therapy of parkin-associated disorders
US20050069918A1 (en) 2003-05-29 2005-03-31 Francois Claret JAB1 as a prognostic marker and a therapeutic target for human cancer
RU2376371C2 (ru) 2003-06-18 2009-12-20 Дженелюкс Корпорейшн Модифицированные рекомбинантные вакцинирующие вирусы и другие микроорганизмы и их применение
WO2005013901A2 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
US8106180B2 (en) 2003-08-07 2012-01-31 Whitehead Institute For Biomedical Research Methods and products for expression of micro RNAs
US20050037362A1 (en) 2003-08-11 2005-02-17 Eppendorf Array Technologies, S.A. Detection and quantification of siRNA on microarrays
US8412541B2 (en) 2003-08-14 2013-04-02 Edda Technology, Inc. Method and system for intelligent qualitative and quantitative analysis for medical diagnosis
WO2005020795A2 (en) 2003-08-25 2005-03-10 The Johns Hopkins University Method of diagnosis and treatment of pancreatic endocrine neoplasms based on differntial gene expression analysis
CA2539651A1 (en) 2003-09-22 2005-04-07 Rosetta Inpharmatics Llc Synthetic lethal screen using rna interference
JP2007506425A (ja) 2003-09-24 2007-03-22 オンコセラピー・サイエンス株式会社 肝細胞癌を診断する方法
WO2005047477A2 (en) 2003-11-07 2005-05-26 University Of Massachusetts Interspersed repetitive element rnas as substrates, inhibitors and delivery vehicles for rnai
US20050164252A1 (en) 2003-12-04 2005-07-28 Yeung Wah Hin A. Methods using non-genic sequences for the detection, modification and treatment of any disease or improvement of functions of a cell
DE602004031881D1 (de) 2003-12-19 2011-04-28 Univ California Verfahren und materialien zur beurteilung von prostatakrebstherapien
WO2005078096A2 (en) * 2004-02-09 2005-08-25 University Of Massachusetts Dual functional oligonucleotides for use in repressing mutant gene expression
WO2005078139A2 (en) 2004-02-09 2005-08-25 Thomas Jefferson University DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES
WO2005079397A2 (en) 2004-02-13 2005-09-01 Rockefeller University Anti-microrna oligonucleotide molecules
AU2005214286A1 (en) 2004-02-23 2005-09-01 Erasmus University Medical Center Rotterdam Classification, diagnosis and prognosis of acute myeloid leukemia by gene expression profiling
US7365058B2 (en) 2004-04-13 2008-04-29 The Rockefeller University MicroRNA and methods for inhibiting same
EP1745150A4 (en) 2004-04-20 2008-02-27 Genaco Biomedial Products Inc METHOD FOR DETECTING NCRNA
EP2322650A1 (en) 2004-05-14 2011-05-18 Rosetta Genomics Ltd MicroRNAs and uses thereof
EP2290072B1 (en) * 2004-05-28 2014-12-17 Asuragen, Inc. Methods and compositions involving microRNA
US7635563B2 (en) 2004-06-30 2009-12-22 Massachusetts Institute Of Technology High throughput methods relating to microRNA expression analysis
US20060037088A1 (en) 2004-08-13 2006-02-16 Shulin Li Gene expression levels as predictors of chemoradiation response of cancer
JP2008511678A (ja) 2004-09-02 2008-04-17 イェール ユニバーシティ マイクロｒｎａによるオンコジーンの調節
US7592441B2 (en) 2004-10-04 2009-09-22 Rosetta Genomics Ltd Liver cancer-related nucleic acids
US7642348B2 (en) 2004-10-04 2010-01-05 Rosetta Genomics Ltd Prostate cancer-related nucleic acids
FR2877350B1 (fr) 2004-11-03 2010-08-27 Centre Nat Rech Scient IDENTIFICATION ET UTILISATION DE miRNAs IMPLIQUES DANS LA DIFFERENCIATION DE CELLULES ISSUES D'UNE LEUCEMIE MYELOIDE
ES2534304T3 (es) 2004-11-12 2015-04-21 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ATE544774T1 (de) 2004-12-14 2012-02-15 Alnylam Pharmaceuticals Inc Rnai-modulation von mll-af4 und verwendungen dafür
US20060185027A1 (en) 2004-12-23 2006-08-17 David Bartel Systems and methods for identifying miRNA targets and for altering miRNA and target expression
US20070099196A1 (en) 2004-12-29 2007-05-03 Sakari Kauppinen Novel oligonucleotide compositions and probe sequences useful for detection and analysis of micrornas and their target mRNAs
DE602006016739D1 (de) 2005-01-25 2010-10-21 Rosetta Inpharmatics Llc Verfahren zur quantifizierung kleiner rna-moleküle
US8071306B2 (en) 2005-01-25 2011-12-06 Merck Sharp & Dohme Corp. Methods for quantitating small RNA molecules
US20070065840A1 (en) 2005-03-23 2007-03-22 Irena Naguibneva Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAS and their target mRNAS
GB2425311A (en) 2005-04-15 2006-10-25 Ist Superiore Sanita Micro RNA against kit protein
CA2605701C (en) 2005-04-29 2015-12-08 Rockefeller University Human micrornas and methods for inhibiting same
WO2006133022A2 (en) 2005-06-03 2006-12-14 The Johns Hopkins University Compositions and methods for decreasing microrna expression for the treatment of neoplasia
US20070065844A1 (en) 2005-06-08 2007-03-22 Massachusetts Institute Of Technology Solution-based methods for RNA expression profiling
US20060292616A1 (en) 2005-06-23 2006-12-28 U.S. Genomics, Inc. Single molecule miRNA-based disease diagnostic methods
CN101341259B (zh) 2005-08-01 2011-12-21 俄亥俄州立大学研究基金会 用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
WO2007021896A2 (en) 2005-08-10 2007-02-22 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides for use in modulating micro rna and uses thereof
EP1937280B1 (en) 2005-09-12 2014-08-27 The Ohio State University Research Foundation Compositions for the therapy of bcl2-associated cancers
CA2624531A1 (en) 2005-10-05 2007-04-19 Carlo M. Croce Wwox gene, vectors containing the same, and uses in treatment of cancer
US7390792B2 (en) 2005-12-15 2008-06-24 Board Of Regents, The University Of Texas System MicroRNA1 therapies
ES2429404T3 (es) 2006-01-05 2013-11-14 The Ohio State University Research Foundation Procedimientos basados en los microARN para el diagnóstico y el pronóstico del cáncer de pulmón
EP2487261B1 (en) 2006-01-05 2015-07-01 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
JP5490413B2 (ja) 2006-01-05 2014-05-14 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 膵内分泌腫瘍及び膵腺房腫瘍におけるマイクロｒｎａ発現異常
WO2007084485A2 (en) 2006-01-13 2007-07-26 Battelle Memorial Institute Markers for assessing copd-related diseases
CA2646051A1 (en) 2006-03-20 2007-09-27 Carlo M. Croce Microrna fingerprints during human megakaryocytopoiesis
WO2007112097A2 (en) 2006-03-24 2007-10-04 Children's Medical Center Corporation Novel signature self renewal gene expression programs
ES2715625T3 (es) 2006-04-03 2019-06-05 Roche Innovation Ct Copenhagen As Composición farmacéutica que comprende oligonucleótidos antisentido anti-miARN
JP5127821B2 (ja) 2006-04-24 2013-01-23 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション ｍｉＲ１５５トランスジェニックマウスにおけるプレＢ細胞増殖及びリンパ芽球性白血病／高悪性度リンパ腫
WO2008008430A2 (en) 2006-07-13 2008-01-17 The Ohio State University Research Foundation Micro-rna-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases
US20080193943A1 (en) 2006-09-05 2008-08-14 Abbott Laboratories Companion diagnostic assays for cancer therapy
EP2145001A2 (en) 2006-09-19 2010-01-20 Asuragen, Inc. Mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
EP2076599A2 (en) 2006-09-19 2009-07-08 Asuragen, Inc. Mir-200 regulated genes and pathways as targets for therapeutic intervention
WO2008036765A2 (en) 2006-09-19 2008-03-27 Asuragen, Inc. Micrornas differentially expressed in pancreatic diseases and uses thereof
US8071292B2 (en) 2006-09-19 2011-12-06 The Ohio State University Research Foundation Leukemia diagnostic methods
EP2087135B8 (en) 2006-11-01 2013-07-24 The Ohio State University Research Foundation Microrna expression signature for predicting survival and metastases in hepatocellular carcinoma
US8293684B2 (en) 2006-11-29 2012-10-23 Exiqon Locked nucleic acid reagents for labelling nucleic acids
WO2008070082A2 (en) 2006-12-04 2008-06-12 The Johns Hopkins University Stem-progenitor cell specific micro-ribonucleic acids and uses thereof
CN101622350A (zh) 2006-12-08 2010-01-06 奥斯瑞根公司 作为干预治疗靶标的miR-126调控基因和通路
WO2008073920A2 (en) 2006-12-08 2008-06-19 Asuragen, Inc. Mir-21 regulated genes and pathways as targets for therapeutic intervention
DK2104737T3 (da) 2006-12-08 2013-05-27 Asuragen Inc Funktioner og formål for let-7 mikro-RNAer
CA2671194A1 (en) 2006-12-08 2008-06-19 Asuragen, Inc. Mir-20 regulated genes and pathways as targets for therapeutic intervention
US20090175827A1 (en) 2006-12-29 2009-07-09 Byrom Mike W miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
CN103555825B (zh) 2007-01-31 2015-09-30 俄亥俄州立大学研究基金会 用于急性髓细胞白血病(aml)的诊断、预后和治疗的基于微rna的方法和组合物
WO2008124777A1 (en) 2007-04-10 2008-10-16 National Taiwan University Predicting post-treatment survival in cancer patients with micrornas
WO2008136971A1 (en) 2007-04-30 2008-11-13 The Ohio State University Research Foundation Methods for differentiating pancreatic cancer from normal pancreatic function and/or chronic pancreatitis
US20090005336A1 (en) 2007-05-08 2009-01-01 Zhiguo Wang Use of the microRNA miR-1 for the treatment, prevention, and diagnosis of cardiac conditions
US20090232893A1 (en) 2007-05-22 2009-09-17 Bader Andreas G miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20090131354A1 (en) 2007-05-22 2009-05-21 Bader Andreas G miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
WO2008154098A2 (en) 2007-06-07 2008-12-18 Wisconsin Alumni Research Foundation Reagents and methods for mirna expression analysis and identification of cancer biomarkers
ES2527648T3 (es) 2007-06-08 2015-01-28 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Métodos para determinar el subtipo de carcinoma hepatocelular
US20090227533A1 (en) 2007-06-08 2009-09-10 Bader Andreas G miR-34 Regulated Genes and Pathways as Targets for Therapeutic Intervention
US8053186B2 (en) 2007-06-15 2011-11-08 The Ohio State University Research Foundation Oncogenic ALL-1 fusion proteins for targeting Drosha-mediated microRNA processing
CA2695184A1 (en) 2007-07-31 2009-02-05 The Ohio State University Research Foundation Methods for reverting methylation by targeting dnmt3a and dnmt3b
ES2570359T3 (es) 2007-08-03 2016-05-18 Univ Ohio State Res Found Regiones ultraconservadas que codifican ARNnc
EP3028708A1 (en) 2007-08-22 2016-06-08 The Ohio State University Research Foundation Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias
US20090061424A1 (en) 2007-08-30 2009-03-05 Sigma-Aldrich Company Universal ligation array for analyzing gene expression or genomic variations
AU2008296022B2 (en) 2007-09-06 2014-01-23 The Ohio State University Research Foundation MicroRNA signatures in human ovarian cancer
CA2702241A1 (en) 2007-10-11 2009-04-16 The Ohio State University Research Foundation Methods and compositions for the diagnosis and treatment of esophageal adenocarcinomas
JP2011504093A (ja) 2007-10-26 2011-02-03 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 脆弱性ヒスチジン三連構造（ｆｈｉｔ）相互作用を同定するための方法およびその使用
EP2217706B1 (en) 2007-11-12 2015-05-27 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Therapeutic applications of p53 isoforms in regenerative medicine, aging and cancer
US20090123933A1 (en) 2007-11-12 2009-05-14 Wake Forest University Health Sciences Microrna biomarkers in lupus
US20100323357A1 (en) 2007-11-30 2010-12-23 The Ohio State University Research Foundation MicroRNA Expression Profiling and Targeting in Peripheral Blood in Lung Cancer
US8071562B2 (en) 2007-12-01 2011-12-06 Mirna Therapeutics, Inc. MiR-124 regulated genes and pathways as targets for therapeutic intervention
US20090192114A1 (en) 2007-12-21 2009-07-30 Dmitriy Ovcharenko miR-10 Regulated Genes and Pathways as Targets for Therapeutic Intervention
CN105734128B (zh) 2008-02-01 2021-05-18 总医院有限公司 微泡在医学疾病和病况的诊断、预后以及治疗中的用途
WO2009100430A2 (en) 2008-02-08 2009-08-13 Asuragen, Inc miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS
EP3064584A3 (en) 2008-02-28 2016-12-07 The Ohio State University Research Foundation Micro rna-based methods and compositions for the diagnosis, prognosis and treatmentof gastric cancer
EP2260109A4 (en) 2008-02-28 2011-06-08 Univ Ohio State Res Found MICRORNA BASED METHOD AND COMPOSITIONS FOR THE DIAGNOSIS, FORECAST AND TREATMENT OF DISEASES RELATED TO THE PROSTATE
AU2009219203B2 (en) 2008-02-28 2014-04-03 The Ohio State University Research Foundation MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia (AML) and uses thereof
EP2254668A4 (en) 2008-02-28 2012-08-15 Univ Ohio State Res Found MICROARN SIGNATURES ASSOCIATED WITH HUMAN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND USES THEREOF
US20090233297A1 (en) 2008-03-06 2009-09-17 Elizabeth Mambo Microrna markers for recurrence of colorectal cancer
EP2271757A2 (en) 2008-03-26 2011-01-12 Asuragen, INC. Compositions and methods related to mir-16 and therapy of prostate cancer
US8258111B2 (en) 2008-05-08 2012-09-04 The Johns Hopkins University Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
US8900627B2 (en) 2008-06-06 2014-12-02 Mirna Therapeutics, Inc. Compositions for the in vivo delivery of RNAi agents
CN102149827B (zh) 2008-06-11 2014-08-20 由卫生与公众服务部代表的美利坚合众国政府 MiR-26家族作为肝细胞癌和对治疗的应答性的预测性标志物的用途
CN102149401A (zh) 2008-08-12 2011-08-10 俄亥俄州立大学研究基金会 用于多发性骨髓瘤的诊断、预后和治疗的基于微rna的组合物和方法
WO2010059779A1 (en) 2008-11-21 2010-05-27 The Ohio State University Research Foundation Tcl1 AS A TRANSCRIPTIONAL REGULATOR
US20110275534A1 (en) 2008-12-05 2011-11-10 The Ohio State University MicroRNA-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Ovarian Cancer Using a Real-Time PCR Platform
WO2010099161A1 (en) 2009-02-26 2010-09-02 The Ohio State University Research Foundation Micrornas in never-smokers and related materials and methods

Also Published As

Publication number Publication date
EP2514433B1 (en) 2015-10-21
CN103993082A (zh) 2014-08-20
EP2502630A2 (en) 2012-09-26
WO2007081720A3 (en) 2008-02-14
EP2514434A3 (en) 2013-02-13
EP1978986B1 (en) 2013-08-07
AU2007205234B2 (en) 2012-07-12
EP2514434A2 (en) 2012-10-24
JP2009531018A (ja) 2009-09-03
EP1978986A4 (en) 2009-12-09
CA2633674A1 (en) 2007-07-19
CN103993082B (zh) 2017-01-11
EP2514433A2 (en) 2012-10-24
CN102943108B (zh) 2014-05-21
ES2429404T3 (es) 2013-11-14
EP2502630A3 (en) 2013-02-13
EP2514434B1 (en) 2015-10-21
CN101400361B (zh) 2012-10-17
US20110190160A1 (en) 2011-08-04
ES2536438T3 (es) 2015-05-25
CN102943108A (zh) 2013-02-27
US20080306017A1 (en) 2008-12-11
AU2007205234A1 (en) 2007-07-19
ES2553442T3 (es) 2015-12-09
US7943318B2 (en) 2011-05-17
EP2502630B1 (en) 2015-03-11
WO2007081720A2 (en) 2007-07-19
EP2514433A3 (en) 2013-02-13
CN101400361A (zh) 2009-04-01
US8361710B2 (en) 2013-01-29
EP1978986A2 (en) 2008-10-15
US20110177968A1 (en) 2011-07-21
US8377637B2 (en) 2013-02-19
JP5451077B2 (ja) 2014-03-26

Similar Documents

Publication Publication Date Title
ES2554531T3 (es) Procedimientos basados en los microARN para el diagnóstico, pronóstico y tratamiento del cáncer de pulmón
ES2545360T3 (es) Métodos basados en microARN y composiciones para el diagnóstico y tratamiento de cánceres sólidos
CN101384273B (zh) 胰腺内分泌和腺泡肿瘤中的微小rna表达异常
JP2008519606A5 (es)
AU2014203454B2 (en) MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
AU2013245505A1 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
HK1132302B (en) Micrornarna-based methods and compositions for the diagnosis and treatment of solid cancers